SG Americas Securities LLC Buys 548 Shares of Sanofi (NASDAQ:SNY)

SG Americas Securities LLC boosted its stake in Sanofi (NASDAQ:SNY) by 3.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,068 shares of the company’s stock after purchasing an additional 548 shares during the quarter. SG Americas Securities LLC’s holdings in Sanofi were worth $868,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Dynamic Advisor Solutions LLC grew its stake in Sanofi by 39.2% during the first quarter. Dynamic Advisor Solutions LLC now owns 57,204 shares of the company’s stock valued at $2,780,000 after acquiring an additional 16,117 shares in the last quarter. Manning & Napier Advisors LLC purchased a new position in shares of Sanofi during the 2nd quarter valued at $13,725,000. Mount Yale Investment Advisors LLC grew its position in shares of Sanofi by 44.3% during the 1st quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock valued at $2,027,000 after purchasing an additional 12,806 shares in the last quarter. Jennison Associates LLC raised its position in shares of Sanofi by 18.9% in the first quarter. Jennison Associates LLC now owns 189,622 shares of the company’s stock worth $9,216,000 after buying an additional 30,115 shares in the last quarter. Finally, Sei Investments Co. raised its position in shares of Sanofi by 9.3% in the first quarter. Sei Investments Co. now owns 554,028 shares of the company’s stock worth $26,926,000 after buying an additional 47,297 shares in the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $54.96 on Friday. The stock has a market cap of $139.46 billion, a price-to-earnings ratio of 29.87, a P/E/G ratio of 1.57 and a beta of 0.60. The stock’s 50-day moving average is $55.81 and its 200 day moving average is $51.33. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a 1-year low of $42.63 and a 1-year high of $58.97.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. During the same period last year, the firm posted $0.95 earnings per share. The business’s revenue was up 7.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Sanofi will post 4.25 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Finally, Argus boosted their price target on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.